New 52 Week Low Today

Rubius Therapeutics Inc RUBY:NASDAQ

RT Quote | Last NYSE, VOL From CTA | USD
Last | 12:20 PM EST
0.202quote price arrow down-0.0051 (-2.4626%)
Volume
222,544
52 week range
0.20 - 13.52
Loading...
  • Open0.2141
  • Day High0.2141
  • Day Low0.202
  • Prev Close0.2071
  • 52 Week High13.52
  • 52 Week High Date12/13/21
  • 52 Week Low0.20
  • 52 Week Low Date11/30/22

Key Stats

  • Market Cap18.255M
  • Shares Out90.37M
  • 10 Day Average Volume0.38M
  • Dividend-
  • Dividend Yield-
  • Beta2.39
  • YTD % Change-97.9

KEY STATS

  • Open0.2141
  • Day High0.2141
  • Day Low0.202
  • Prev Close0.2071
  • 52 Week High13.52
  • 52 Week High Date12/13/21
  • 52 Week Low0.20
  • 52 Week Low Date11/30/22
  • Market Cap18.255M
  • Shares Out90.37M
  • 10 Day Average Volume0.38M
  • Dividend-
  • Dividend Yield-
  • Beta2.39
  • YTD % Change-97.9

RATIOS/PROFITABILITY

  • EPS (TTM)-2.38
  • P/E (TTM)-0.08
  • Fwd P/E (NTM)-0.17
  • EBITDA (TTM)-169.806M
  • ROE (TTM)-164.54%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)209.99%

EVENTS

  • Earnings Date02/23/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Rubius Therapeutics Inc

 

Profile

MORE
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune...
Pablo Cagnoni M.D.
Chairman of the Board
Dannielle Appelhans
President, Chief Executive Officer, Chief Operating Officer
Address
399 Binney St Ste 300
Cambridge, MA
02142-1038
United States

Top Peers

SYMBOLLASTCHG%CHG
APRE
Aprea Therapeutics Inc
0.3899UNCHUNCH
NNVC
NanoViricides Inc
1.63-0.01-0.65%
APTX
Aptinyx Inc
0.2849+0.0049+1.75%
NLTX
Neoleukin Therapeutics Inc
0.48-0.0201-4.0192%
FWP
Forward Pharma A/S
2.93+0.01+0.34%